newsfilter
← Latest News
Business Wire·

TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results

– Completed strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical settings – - Announced OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study of SM-88 used wi